USF Breast Health Program is committed to using the latest technologies for treating
breast cancer. The following is a list of some of
the technology currently in use.
Cryoablation kills tumor cells by freezing them.
This may be an effective treatment for patients with invasive ductal
This is a clinical trial that is currently in progress.
Please click on the following link for more information:
Dr. John Cox, of Tampa Bay Breast Care Specialists, recently recorded a video of the Cryoablation procedure
for PBS, which aired on March 18, 2011. Please click on the
following link to view it.
HALO Breast Pap Test
- HALO is noninvasive, objective and repeatable, plus it's quick -
just 5 minutes
- HALO has been proven a safe and effective method to collect nipple
aspirate fluid for analysis
- Routine assessment with HALO will enable breast health monitoring
and the ability to react to cellular changes early
The HALO® Breast Pap Test is FDA approved for the
collection of nipple aspirate fluid for cytological evaluation. The
collected fluid can be used in the determination and/or
differentiation of normal versus pre-malignant versus malignant
Incorporating Halo into routine practice will enable physicians and
patients to monitor cellular changes within breast ducts earlier,
before they develop into larger, potentially cancerous lesions.
Xoft Axxent® eBx System for breast brachytherapy:
The Xoft Axxent® eBx System for breast brachytherapy is
designed to simplify the radiation therapy procedure and increase
accessibility to patients who are suitable candidates for partial-breast
irradiation (PBI). Breast eBx with the Axxent System delivers a prescribed,
targeted dose of radiation directly to the site where cancer recurrence is
most likely. Compared to traditional radiotherapy, eBx requires fewer
treatments and minimizes exposure to healthy tissue and organs, such as the
ribs, lungs, heart and opposite breast (Reduced
Dose to Heart and Lungs
). Patients also experience
low rates of serious complications and favorable cosmetic outcomes.
MammaPrint gene expression profiling
MammaPrint is a gene
expression profiling system to assess the risk of cancer
recurrence in patients with breast cancer. The system is based
on the expression of 70 of the most informative genes in the
tumor, quantified simultaneously to ensure a high degree of
accuracy in determining the risk of breast cancer recurrence.
MammaPrint result are indicated for use by physicians as a
prognostic marker in combination with other clinical information
and laboratory tests. MammaPrint is also the first in vitro
diagnostic multivariate index assay (IVDMIA) to acquire market
clearance from the FDA.